33 results on '"Franck N"'
Search Results
2. Introduction
- Author
-
Franck, N., primary
- Published
- 2023
- Full Text
- View/download PDF
3. Programme GAÏA
- Author
-
Gaudelus, B., primary and Franck, N., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Remédiation de la cognition sociale dans la schizophrénie (RC2S+)
- Author
-
Peyroux, E., primary and Franck, N., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Comment pallier les déficits cognitifs ?
- Author
-
Franck, N., primary
- Published
- 2019
- Full Text
- View/download PDF
6. Historique et fondamentaux
- Author
-
Morin, L., primary and Franck, N., additional
- Published
- 2016
- Full Text
- View/download PDF
7. Schizophrénie et autres troubles psychotiques
- Author
-
Franck, N., primary
- Published
- 2012
- Full Text
- View/download PDF
8. Liste des auteurs
- Author
-
Amado, I., primary, Bardy-Linder, S., additional, Bazin, N., additional, Brana, A., additional, Coste, M.-H., additional, Demily, C., additional, Duboc, C., additional, Favrod, J., additional, Fourneret, P., additional, Franck, N., additional, Gaudelus, B., additional, Giraud-Baro, É., additional, Gremaud, K., additional, Grynszpan, O., additional, Hayoz, C., additional, Jouvent, R., additional, Komano, O., additional, Krolak-Salmon, P., additional, Moritz, S., additional, Pachoud, B., additional, Passerieux, C., additional, Peyroux, É., additional, Pomini, V., additional, Prouteau, A., additional, Rexhaj, S., additional, Roder, V., additional, Roussel, C., additional, Royer, A., additional, Samama, D., additional, Schneider, F., additional, Seguin, C., additional, Todd, A., additional, Vianin, P., additional, and Voisin, C., additional
- Published
- 2012
- Full Text
- View/download PDF
9. Introduction
- Author
-
Franck, N., primary
- Published
- 2012
- Full Text
- View/download PDF
10. Psychiatry Res
- Author
-
VERDOUX, Helene, QUILES, C., CERVELLO, S., DUBREUCQ, J., BON, L., MASSOUBRE, C., POMMIER, R., LEGROS-LAFARGE, E., JAAFARI, N., GUILLARD-BOUHET, N., CHEREAU-BOUDET, I., COUHET, G., PLASSE, J., and FRANCK, N.
- Published
- 2019
11. Comparative countries’ tourism technical efficiency assessment: A stochastic output distance function approach
- Author
-
Alastaire Sèna Alinsato, Nassibou Bassongui, and Franck Nkeudjoua Wondeu
- Subjects
L83 ,D24 ,C23 ,Science - Abstract
This study aims at analysing the technical efficiency of the tourism industry worldwide. Using a sample of 111 countries worldwide from 2008 to 2016, we estimated the tourism industry technical efficiency score to measure of the industry performance from a translog output distance function modelling. Our results showed that high-income countries are more efficient because of higher qualified labour, and higher productivity of natural and cultural resources. Besides, our results support that African and Asian countries are less efficient than those from Europe and America. For international comparison purposes, our findings suggested that the level of income and the location of destinations should be incorporated as determinants and inputs of the tourism production function to the technical efficiency. In the political view, policymakers are encouraged to be aware of the income level of their citizens to improve the performance of their tourism sector.
- Published
- 2022
- Full Text
- View/download PDF
12. Chromatin Redistribution of the DEK Oncoprotein Represses hTERT Transcription in Leukemias
- Author
-
Maroun Karam, Morgan Thenoz, Valérie Capraro, Jean-Philippe Robin, Christiane Pinatel, Agnès Lançon, Perrine Galia, David Sibon, Xavier Thomas, Sophie Ducastelle-Lepretre, Franck Nicolini, Mohamed El-Hamri, Youcef Chelghoun, Eric Wattel, and Franck Mortreux
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Although numerous factors have been found to modulate hTERT transcription, the mechanism of its repression in certain leukemias remains unknown. We show here that DEK represses hTERT transcription through its enrichment on the hTERT promoter in cells from chronic and acute myeloid leukemias, chronic lymphocytic leukemia, but not acute lymphocytic leukemias where hTERT is overexpressed. We isolated DEK from the hTERT promoter incubated with nuclear extracts derived from fresh acute myelogenous leukemia (AML) cells and from cells expressing Tax, an hTERT repressor encoded by the human T cell leukemia virus type 1. In addition to the recruitment of DEK, the displacement of two potent known hTERT transactivators from the hTERT promoter characterized both AML cells and Tax-expressing cells. Reporter and chromatin immunoprecipitation assays permitted to map the region that supports the repressive effect of DEK on hTERT transcription, which was proportionate to the level of DEK-promoter association but not with the level of DEK expression. Besides hTERT repression, this context of chromatin redistribution of DEK was found to govern about 40% of overall transcriptional modifications, including those of cancer-prone genes. In conclusion, DEK emerges as an hTERT repressor shared by various leukemia subtypes and seems involved in the deregulation of numerous genes associated with leukemogenesis.
- Published
- 2014
- Full Text
- View/download PDF
13. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
- Author
-
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, and Peffault de Latour R
- Subjects
- Humans, Prospective Studies, Propensity Score, Transplantation, Homologous, Sezary Syndrome therapy, Sezary Syndrome etiology, Lymphoma, T-Cell, Cutaneous therapy, Lymphoma, T-Cell, Cutaneous etiology, Hematopoietic Stem Cell Transplantation methods, Mycosis Fungoides etiology, Mycosis Fungoides pathology, Skin Neoplasms therapy, Skin Neoplasms etiology
- Abstract
Background: Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs., Methods: In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy. Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sézary syndrome, and at least one poor prognostic criteria. Participants were excluded if they were not in complete or partial remission of the disease. Propensity score 1:1 matching with replacement (ie, that each participant treated with HSCT was matched to the participant with the closest propensity score treated with non-HSCT therapy, even if they had already been matched) was used to handle confounding factors, with the balance of covariate distribution between HSCT and non-HSCT groups assessed using standardised mean differences. The primary endpoint was progression-free survival in the matched intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02520908), and is currently active but not recruiting., Findings: From June 1, 2016, to March 3, 2022, total of 99 participants were enrolled at 17 centres in France. Participants with a sibling or matched unrelated donor were assigned to allogeneic HSCT (HSCT group, n=55 [56%]) and participants without a donor were assigned to non-allogeneic HSCT treatment (non-HSCT group, n=44 [44%]). The median follow-up among survivors was 12·6 months (IQR 11·0-35·2). In the HSCT group, 51 participants (93%) were 1:1 matched to participants from the non-HSCT group. In the intention-to-treat analysis, median progression-free survival was significantly longer in the HSCT group (9·0 months [95% CI 6·6-30·5]) than in the non-HSCT group (3·0 months [2·0-6·3]), with a hazard ratio of 0·38 (95% CI 0·21-0·69; p<0·0001). In the per-protocol population, 40 participants (78%) in the HSCT group had 101 serious events and 29 participants (67%) in the non-HSCT group had 70 serious adverse events. The most common serious adverse event other than graft-versus-host disease in both groups was infections, occurring in 30 participants (59%) in the HSCT group and in 19 participants (44%) in the non-HSCT group., Interpretation: Allogeneic HSCT was associated with significantly longer progression-free survival in participants with advanced-stage CTCLs. These results indicate that allogeneic HSCT treatment should be made available to individuals with high-risk, advanced-stage mycosis fungoides or Sézary syndrome who achieve pre-transplant disease remission., Funding: French Ministry of Health, National Cancer Institute, Programme Hospitalier de Recherche Clinique en Cancérologie., Competing Interests: Declaration of interests AdM reports research funding from Innate, Almirall, and Kyowa Kirin; travel expenses from Kyowa Kirin, Recordati Rare Diseases and Orphan Europe, and Janssen-Cilag; and fees from Takeda. MB-B reports consultancy at Kyowa Kirin and Recordati; and research funding from Celgene and Roche. SD reports institutional grants from Bristol Myers Squibb and Merck Sharp & Dohme. SI-H-O reports consultancy for Takeda and Recordati. CO reports honoraria from Novartis. JA reports honoraria from Roche and Janssen. OD reports consultancy from Bristol Myers Squibb, Kyowa Kirin, Merck, Sharpe & Dohme, Novartis, Pierre Fabre, Recordati Rare Diseases, Sanofi, and Sun Pharma; honoraria from Bristol Myers Squibb, Kyowa Kirin, LeoPharma, Merck, Sharpe & Dohme, Novartis, Pierre Fabre, Recordati Rare Diseases, Sanofi, and Sun Pharma; registration to meetings from Bristol Myers Squibb, Kyowa Kirin, LeoPharma, Merck, Sharpe & Dohme, Novartis, and Pierre Fabre; grants from Pierre Fabre; research funding from Kyowa Kirin, Novartis, and Pierre Fabre; and travel expenses from Bristol Myers Squibb, Janssen, Kyowa Kirin, LeoPharma, Merck, Sharpe & Dohme, Novartis, Pierre Fabre, and Sanofi. SBa reports consultancy at Amgen and Blueprint Medicines; and honoraria from Novartis, Leo Laboratories, and AbbVie. EW-H reports consultancy at Novartis, Bristol Myers Squibb, Pierre Fabre, BluePrint, Sun Pharma, AbbVie, and Sanofi; research funding from AbbVie; and honoraria from Bristol Myers Squibb, Novartis, AbbVie, Sanofi, and Pierre Fabre. FA reports consultancy at AbbVie, Almirall, Amgen, Bristol Myers Squibb, Janssen-Cilag, Leo, Merck Sharp & Dohme, Novartis, Pierre Fabre, Sanofi, and Union Chimique Belge; honoraria from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Janssen-Cilag, Leo, Merck Sharp & Dohme, Novartis, Pierre Fabre, Sanofi, and Union Chimique Belge; and research funding from Galderma, Janssen, and Pfizer. RH reports honoraria from Kite and Gilead, Novartis, Incyte, Janssen, Merck Sharp & Dohme, Takeda, and Roche; and consultancy at Kite and Gilead, Novartis, Bristol Myers Squibb and Celgene, ADC Therapeutics, Incyte, and Miltenyi. AP-L reports honoraria from Bristol Myers Squibb and Novartis; and travel accommodation and meeting participation from Kyowa Kirin, Recordati, Novartis, and Bristol Myers Squibb. DM reports honoraria from Novartis, Incyte, CSL Behring, and Jazz Pharmaceuticals. J-DB reports being on a speaker or advisory board member for Boehringer-Ingelheim, Janssen, Novartis, Union Chimique Belge, Leo, AbbVie, Eli Lilly, Pfizer, Sanofi, and Almirall. FG reports consultancy at Recordati Rare Disease, Kyowa Kirin, Novartis, Pierre Fabre, Bristol Myers Squibb, and Merck Sharp & Dohme. HM-T reports consultancy at Innate; and research funding from Kyowa Kirin. SMo reports honoraria from Novartis, Pierre Fabre, Roche and Biocartis; and research funding from Novartis and Bristol Myers Squibb. MBat reports consultancy at Bristol Myers Squibb and Quantum Genomics; honoraria from Innate, Kyowa Kirin, Takeda, Meccellis Biotech, Cerba Research, and Sanofi; research funding from Kyowa Kirin; and grants from Takeda. ED reports grants from Pfizer and Mallinckrodt; and consultancy at Swedish Orphan Biovitrum. ML reports honoraria from Novartis, Pfizer, Alexion Pharmaceuticals, Sandoz, Novartis, Sanofi, Swedish Orphan Biovitrum, Gilead, and Bristol Myers Squibb. AP reports consultancy and honoraria from Novartis, Pierre-Fabre, Bristol Myers Squibb, Merck Sharp & Dohme, and Sun Pharma. AH reports consultancy at Novartis, Astellas, Jazz Pharmaceuticals, and Pfizer; and honoraria from Novartis, Astellas, Jazz Pharmaceuticals, and Pfizer. YLC reports consultancy at Novartis, Merck Sharp & Dohme, Bristol Myers Squibb, and Pierre Fabre Oncologie; and honoraria from Novartis, Leo, AbbVie, Pfizer, and Pierre Fabre Oncologie. EF reports participation in advisory board at Gilead, GSK, and Sanofi; speakers bureau from Novartis and Alexion; honoraria from Novartis; and travel grants from Gilead, Merck Sharp & Dohme, Jazz Pharmaceuticals, and Novartis. GS reports consultancy at Novartis and Alexion Pharmaceuticals; honoraria from Novartis, Incyte, and Alexion Pharmaceuticals; and research funding from Alexion Pharmaceuticals. RPdL reports consultancy at Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; honoraria from Novartis, Pfizer, Amgen, Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Swedish Orphan Biovitrum; research funding from Novartis, Pfizer, Amgen, and Alexion Pharmaceuticals; and grants from Alexion Pharmaceuticals, Amgen, Novartis, and Pfizer. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Who maintains good mental health in a locked-down country? A French nationwide online survey of 11,391 participants.
- Author
-
Haesebaert F, Haesebaert J, Zante E, and Franck N
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Communicable Disease Control methods, Female, France, Humans, Male, Middle Aged, Pandemics, Residence Characteristics statistics & numerical data, Surveys and Questionnaires, Young Adult, COVID-19 prevention & control, COVID-19 psychology, Mental Health, Quarantine methods, Quarantine psychology
- Abstract
Lockdown measures can differentially affect mental wellbeing in populations depending on individual determinants. We aim to investigate the sociodemographic and environmental determinants of wellbeing on the French population during lockdown due to the SARS-CoV-2 pandemic with an online survey. Among 11,391 participants who completed the questionnaire, various factors negatively impacted wellbeing: being a female, a student, disabled, having no access to outdoor spaces, or living in a small home. Conversely, being employed and having more social contacts had a positive impact. During lockdowns, authorities should consider the vulnerability of specific populations, especially when they live in constrained housing conditions., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
15. Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report.
- Author
-
Charvet E, Lheure C, Isnard C, Franck N, Kramkimel N, Vallet-Pichard A, Dohan A, Terris B, Aractingi S, Dupin N, and Guégan S
- Subjects
- Antibodies, Monoclonal adverse effects, Humans, Nivolumab adverse effects, Hepatic Veno-Occlusive Disease chemically induced, Melanoma drug therapy
- Abstract
Competing Interests: Disclosure The authors have declared no conflicts of interest.
- Published
- 2020
- Full Text
- View/download PDF
16. HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma.
- Author
-
Sonigo G, Battistella M, Beylot-Barry M, Ingen-Housz-Oro S, Franck N, Barete S, Boulinguez S, Dereure O, Bonnet N, Socié G, Brice P, Boccara O, Bodemer C, Adamski H, D'Incan M, Ortonne N, Fraitag S, Brunet-Possenti F, Dalle S, Suarez F, Marçais A, Skowron F, Haidar D, Maubec E, Bohelay G, Laroche L, Mahé A, Birckel E, Bouaziz JD, Brocheriou I, Dubois R, Faiz S, Fadlallah J, Ram-Wolff C, Carlotti A, Bens G, Balme B, Vergier B, Laurent-Roussel S, Deschamps L, Carpentier O, Moguelet P, Herve G, Comoz F, Le Gall F, Leverger G, Finon A, Augereau O, Bléchet C, Kerdraon R, Lamant L, Tournier E, Franck F, Costes-Martineau V, Szablewski V, Taix S, Beschet I, Guerin F, Sepulveda FE, Bagot M, de Saint Basile G, Michonneau D, and de Masson A
- Subjects
- Biomarkers, Female, Genetic Association Studies, Humans, Male, Genetic Predisposition to Disease, Hepatitis A Virus Cellular Receptor 2 genetics, Lymphohistiocytosis, Hemophagocytic diagnosis, Lymphohistiocytosis, Hemophagocytic genetics, Lymphoma, T-Cell diagnosis, Lymphoma, T-Cell genetics, Mutation, Panniculitis diagnosis, Panniculitis genetics
- Published
- 2020
- Full Text
- View/download PDF
17. Exploratory case study of monozygotic twins with 22q11.2DS provides further clues to circumscribe neurocognitive markers of psychotic symptoms.
- Author
-
Favre E, Leleu A, Peyroux E, Baudouin JY, Franck N, and Demily C
- Subjects
- Adult, Biomarkers, DiGeorge Syndrome complications, Electroencephalography, Endophenotypes, Humans, Male, Psychotic Disorders etiology, Twins, Monozygotic, Young Adult, Cerebral Cortex physiopathology, DiGeorge Syndrome physiopathology, Emotions physiology, Facial Recognition physiology, Psychotic Disorders physiopathology, Social Perception
- Abstract
Variation in facial emotion processing abilities may contribute to variability in penetrance for psychotic symptoms in 22q11.2DS. However, the precise nature of the social cognitive dysfunction (i.e., facial expression perception vs. emotion recognition), the potential additional roles of genetic and environmental variabilities, and consequently the possibility of using this neurocognitive marker in clinical monitoring remain unclear. The present case study aimed at testing the hypothesis that when confounding factors are controlled, the presence of psychotic symptoms in 22q11.2DS is associated, at the individual level, with a neural marker of facial expression perception rather than explicit emotional face recognition. Two monozygotic twins with 22q11.2DS discordant for psychiatric manifestations performed (1) a classical facial emotion labelling task and (2) an implicit neural measurement of facial expression perception using a frequency-tagging approach in electroencephalography (EEG). Analysis of the periodic brain response elicited by a change of facial expression from neutrality indicated that the twin with psychotic symptoms did not detect emotion among neutral faces while the twin without the symptoms did. In contrast, both encountered difficulties labelling facial emotion. The results from this exploratory twin study support the idea that impaired facial expression perception rather than explicit recognition of the emotion expressed might be a neurocognitive endophenotype of psychotic symptoms that could be reliable at a clinical level. Although confirmatory studies should be required, it facilitates further discussion on the etiology of the clinical phenotype in 22q11.2DS., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
18. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
- Author
-
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, and Joly P
- Subjects
- Humans, Pemphigus immunology, Severity of Illness Index, Validation Studies as Topic, Autoantibodies immunology, Autoimmunity, Desmoglein 1 immunology, Pemphigus diagnosis, Skin pathology
- Abstract
The Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (ABSIS) scores have been proposed to provide an objective measure of pemphigus activity. These scores have been evaluated only on already treated patients mainly with mild to moderate activity. The objective was to assess the interrater reliability of ABSIS and PDAI scores and their correlation with other severity markers in a large international study. Consecutive patients with newly diagnosed pemphigus were enrolled in 31 centers. Severity scores were recorded during a 24-month period by the same two blinded investigators. Serum was collected at each visit for ELISA measurement of anti-desmoglein antibodies. The intraclass correlation coefficient (ICC) and Spearman rank correlation coefficient were calculated. A total of 116 patients with pemphigus vulgaris (n = 84) or pemphigus foliaceus (n = 32) were included. At baseline, the ABSIS and PDAI ICCs were 0.90 (95% confidence interval [CI] = 0.85-0.93), and 0.91(95% CI = 0.87-0.94), respectively. The ICCs for PDAI were higher in moderate and extensive pemphigus (ICC = 0.82, 95% CI = 0.63-0.92 and ICC = 0.80, 95% CI = 0.62-0.90, respectively) than in patients with intermediate (significant) extent (ICC = 0.50, 95% CI = 0.27-0.68). Conversely, the ICCs for ABSIS were lower in patients with moderate extent (ICC = 0.44, 95% CI = 0.004-0.74) than in those with intermediate or extensive forms, (ICC = 0.69, 95% CI = 0.51-0.81 and ICC = 0.75, 95% CI = 0.51-0.88, respectively). During patients' follow-up, the ICCs of both ABSIS and PDAI scores remained higher than 0.70. ABSIS and PDAI skin (r = 0.71 and r = 0.75) but not mucosal (r = 0.32 and r = 0.37) subscores were correlated with the evolution of anti-DSG1 and anti-DSG3 ELISA values, respectively. ABSIS and PDAI scores are robust tools to accurately assess pemphigus activity., (Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
19. Cognitive behavioral therapy in 22q11.2 microdeletion with psychotic symptoms: What do we learn from schizophrenia?
- Author
-
Demily C and Franck N
- Subjects
- Attention Deficit Disorder with Hyperactivity genetics, Attention Deficit Disorder with Hyperactivity physiopathology, Attention Deficit Disorder with Hyperactivity therapy, Humans, Psychotic Disorders physiopathology, Psychotic Disorders therapy, Schizophrenia physiopathology, Cognitive Behavioral Therapy, DiGeorge Syndrome genetics, Psychotic Disorders genetics, Schizophrenia genetics
- Abstract
The 22q11.2 deletion syndrome (22q11.2DS) is one of the most common microdeletion syndromes, with a widely underestimated prevalence between 1 per 2000 and 1 per 6000. Since childhood, patients with 22q11.2DS are described as having difficulties to initiate and maintain peer relationships. This lack of social skills has been linked to attention deficits/hyperactivity disorder, anxiety and depression. A high incidence of psychosis and positive symptoms is observed in patients with 22q11.2DS and remains correlated with poor social functioning, anxiety and depressive symptoms. Because 22q11.2DS and schizophrenia share several major clinical features, 22q11.2DS is sometimes considered as a genetic model for schizophrenia. Surprisingly, almost no study suggests the use of cognitive and behavioral therapy (CBT) in this indication. We reviewed what should be learned from schizophrenia to develop specific intervention for 22q11.2DS. In our opinion, the first step of CBT approach in 22q11.2DS with psychotic symptoms is to identify precisely which tools can be used among the already available ones. Cognitive behavioral therapy (CBT) targets integrated disorders, i.e. reasoning biases and behavior disorders. In 22q11.2DS, CBT-targeted behavior disorders may take the form of social avoidance and withdrawal or, in the contrary, a more unusual disinhibition and aggressiveness. In our experience, other negative symptoms observed in 22q11.2DS, such as motivation deficit or anhedonia, may also be reduced by CBT. Controlled trials have been studying the benefits of CBT in schizophrenia and several meta-analyses proved its effectiveness. Therefore, it is legitimate to propose this tool in 22q11.2DS, considering symptoms similarities. Overall, CBT is the most effective psychosocial intervention on psychotic symptoms and remains a relevant complement to pharmacological treatments such as antipsychotics., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
20. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.
- Author
-
Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, Franck N, Kramkimel N, Borden A, Touat M, Ricard D, Verny M, Maisonobe T, and Psimaras D
- Subjects
- Aged, 80 and over, Deltoid Muscle pathology, Female, Humans, Lung Neoplasms diagnosis, Lung Neoplasms drug therapy, Lung Neoplasms secondary, Melanoma diagnosis, Myositis pathology, Necrosis, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents, Immunological adverse effects, Deltoid Muscle drug effects, Melanoma drug therapy, Myositis chemically induced
- Published
- 2016
- Full Text
- View/download PDF
21. Helical tomotherapy in oncodermatology: case report of circumferential cutaneous lymphoma treated by this optimized radiotherapy.
- Author
-
Servy A, Kramkimel N, Franck N, Park S, and Kirova YM
- Subjects
- Dose Fractionation, Radiation, Female, Humans, Middle Aged, Organs at Risk, Lymphoma, T-Cell, Cutaneous radiotherapy, Radiotherapy, Intensity-Modulated, Skin Neoplasms radiotherapy
- Abstract
Helical tomotherapy is a recent modality of intensity-modulated, rotational irradiation being developed for treatment of an increasing number of malignancies. It allows delivering an accurate treatment while sparing critical organs thus optimizing the therapeutic ratio. In particular, it allows treating some tumour locations that could not be efficiently irradiated through more conventional irradiation devices. We report the usefulness of this approach for the treatment of complex lesions such as circumferential cutaneous lymphoma of the trunk., (Copyright © 2013 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
22. [Childhood onset schizophrenia: current data and therapeutic approach].
- Author
-
Fourneret P, Georgieff N, and Franck N
- Subjects
- Autistic Disorder diagnosis, Developmental Disabilities diagnosis, Diagnosis, Differential, Genetic Predisposition to Disease, Humans, Prognosis, Schizophrenia epidemiology, Schizophrenia etiology, Schizophrenia therapy, Social Environment, Schizophrenia diagnosis
- Abstract
Childhood schizophrenia is a rare but serious developmental disorder affecting most of the fields involved in the child's adaptive functioning: motor, emotional, cognitive, and social. The clinical expression of the disorder mainly depends on the child's age and the IQ level at the time the first clinical symptoms appear. The progression of childhood schizophrenia is generally poor, with different outcome studies suggesting a continuity of the process between childhood and adulthood. This stresses the importance of diagnosing the disorder early and initiating the adapted therapeutic measures as quickly as possible, including cognitive remediation (a new therapeutic tool to correct or anticipate cognitive disorders), which can prevent pejorative development., (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
23. Impaired hierarchical control within the lateral prefrontal cortex in schizophrenia.
- Author
-
Barbalat G, Chambon V, Domenech PJ, Ody C, Koechlin E, Franck N, and Farrer C
- Subjects
- Adult, Brain Mapping methods, Case-Control Studies, Humans, Magnetic Resonance Imaging methods, Male, Mental Processes physiology, Neural Pathways physiopathology, Psychophysiology methods, Models, Statistical, Prefrontal Cortex physiopathology, Schizophrenia physiopathology, Schizophrenic Psychology
- Abstract
Background: In schizophrenia, disturbances of cognitive control have been associated with impaired functional specialization within the lateral prefrontal cortex (LPFC), but little is known about the functional interactions between specialized LPFC subregions. Here, we addressed this question with a recent model that describes the LPFC functioning as a cascade of control processes along a rostrocaudal axis, whereby anterior frontal regions influence the processing in posterior frontal regions to guide action selection on the basis of the temporal structure of information., Methods: We assessed effective connectivity within the rostrocaudal axis of the LPFC by means of functional magnetic resonance imaging in 15 schizophrenic patients and 14 matched healthy control subjects with structural equation modeling and psychophysiological interactions., Results: In healthy subjects, activity in the left caudal LPFC regions was under the influence of left rostral LPFC regions when controlling information conveyed by past events. By contrast, schizophrenic patients failed to demonstrate significant effective connectivity from rostral to caudal LPFC regions in both hemispheres., Conclusions: The hierarchical control along the rostrocaudal axis of the LPFC is impaired in schizophrenia. This provides the first evidence of a top-down functional disconnection within the LPFC in this disorder. This disruption of top-down connectivity from rostral to caudal LPFC regions observed in patients might affect their ability to select the appropriate sets of stimulus-response associations in the caudal LPFC on the basis of information conveyed by past events. This impaired hierarchical control within the LPFC could result from poorly encoded contextual information due to abnormal computations in the caudal LPFC., (Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
24. Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein.
- Author
-
Strid T, Svartz J, Franck N, Hallin E, Ingelsson B, Söderström M, and Hammarström S
- Subjects
- 5-Lipoxygenase-Activating Proteins, Animals, COS Cells, Carrier Proteins antagonists & inhibitors, Chlorocebus aethiops, Fluorescence Resonance Energy Transfer methods, Glutathione Transferase genetics, Humans, Membrane Proteins antagonists & inhibitors, Arachidonate 5-Lipoxygenase metabolism, Carrier Proteins metabolism, Glutathione Transferase metabolism, Membrane Proteins metabolism
- Abstract
Leukotriene C(4) is a potent inflammatory mediator formed from arachidonic acid and glutathione. 5-Lipoxygenase (5-LO), 5-lipoxygenase activating protein (FLAP) and leukotriene C(4) synthase (LTC(4)S) participate in its biosynthesis. We report evidence that LTC(4)S interacts in vitro with both FLAP and 5-LO and that these interactions involve distinct parts of LTC(4)S. FLAP bound to the N-terminal part/first hydrophobic region of LTC(4)S. This part did not bind 5-LO which bound to the second hydrophilic loop of LTC(4)S. Fluorescent FLAP- and LTC(4)S-fusion proteins co-localized at the nuclear envelope. Furthermore, GFP-FLAP and GFP-LTC(4)S co-localized with a fluorescent ER marker. In resting HEK293/T or COS-7 cells GFP-5-LO was found mainly in the nuclear matrix. Upon stimulation with calcium ionophore, GFP-5-LO translocated to the nuclear envelope allowing it to interact with FLAP and LTC(4)S. Direct interaction of 5-LO and LTC(4)S in ionophore-stimulated (but not un-stimulated) cells was demonstrated by BRET using GFP-5-LO and Rluc-LTC(4)S.
- Published
- 2009
- Full Text
- View/download PDF
25. Human, but not rat, IRS1 targets to the plasma membrane in both human and rat adipocytes.
- Author
-
Stenkula KG, Thorn H, Franck N, Hallin E, Sauma L, Nystrom FH, and Strålfors P
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Adipocytes cytology, Animals, Cell Membrane ultrastructure, Cells, Cultured, Insulin Receptor Substrate Proteins, Male, Microscopy, Confocal, Microscopy, Electron, Transmission, Plasmids genetics, Protein Transport, Rats, Rats, Sprague-Dawley, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Transfection, Adaptor Proteins, Signal Transducing metabolism, Adipocytes metabolism, Cell Membrane metabolism
- Abstract
Adipocytes are primary targets for insulin control of metabolism. The activated insulin receptor phosphorylates insulin receptor substrate-1 (IRS1), which acts as a docking protein for downstream signal mediators. In the absence of insulin stimulation, IRS1 in rat adipocytes is intracellular but in human adipocytes IRS1 is constitutively targeted to the plasma membrane. Stimulation of adipocytes with insulin increased the amount of IRS1 at the plasma membrane 2-fold in human adipocytes, but >10-fold in rat adipocytes, with the same final amount of IRS1 at the plasma membrane in cells from both species. Cross-transfection of rat adipocytes with human IRS1, or human adipocytes with rat IRS1, demonstrated that the species difference was due to the IRS1 protein and not the cellular milieus or posttranslational modifications. Chimeric IRS1, consisting of the conserved N-terminus of rat IRS1 with the variable C-terminal of human IRS1, did not target the plasma membrane, indicating that subtle sequence differences direct human IRS1 to the plasma membrane.
- Published
- 2007
- Full Text
- View/download PDF
26. A specific role for efferent information in self-recognition.
- Author
-
Tsakiris M, Haggard P, Franck N, Mainy N, and Sirigu A
- Subjects
- Adult, Cognition, Female, Humans, Male, Proprioception, Visual Perception, Recognition, Psychology, Self Concept
- Abstract
We investigated the specific contribution of efferent information in a self-recognition task. Subjects experienced a passive extension of the right index finger, either as an effect of moving their left hand via a lever ('self-generated action'), or imposed externally by the experimenter ('externally-generated action'). The visual feedback was manipulated so that subjects saw either their own right hand ('view own hand' condition) or someone else's right hand ('view other's hand' condition) during the passive extension of the index finger. Both hands were covered with identical gloves, so that discrimination on the basis of morphological differences was not possible. Participants judged whether the right hand they saw was theirs or not. Self-recognition was significantly more accurate when subjects were themselves the authors of the action, even though visual and proprioceptive information always specified the same posture, and despite the fact that subjects judged the effect and not the action per se. When the passive displacement of the participants right index finger was externally generated, and only afferent information was available, self-recognition performance dropped to near-chance levels. Differences in performance across conditions reflect the distinctive contribution of efferent information to self-recognition, and argue against a dominant role of proprioception in self-recognition.
- Published
- 2005
- Full Text
- View/download PDF
27. Anticipating incoming events: an impaired cognitive process in schizophrenia.
- Author
-
Posada A, Franck N, Georgieff N, and Jeannerod M
- Subjects
- Adult, Analysis of Variance, Consciousness, Female, Humans, Male, Middle Aged, Serial Learning, Space Perception, Time Perception, Cognition, Memory, Short-Term, Psychomotor Performance, Schizophrenic Psychology
- Abstract
Intentions are central to guiding actions to their completion because they generate expectations which precede the realization of a task. This ability to manage time was investigated by using a cognitive task which involves several highly integrated processes: sequential learning, explicit processing, and working memory. In this task, participants are required to explicitly learn a repeating color sequence before receiving an instruction to give an anticipatory motor response concerning the next element. Two types of sequences (temporal and spatial) and three experimental conditions were tested in both a group of normal participants and a group of schizophrenic patients. Schizophrenics were included because their condition is known to alter conscious executive function. Our results showed that schizophrenic patients have a strong deficit in performing anticipation tasks. Although they learned the sequences almost normally, their anticipatory ability was reduced in comparison to normal participants in all the tested conditions. These results expand the notion of a working memory deficit in schizophrenia and bear strong implications for understanding executive disorders observed in such patients.
- Published
- 2001
- Full Text
- View/download PDF
28. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.
- Author
-
Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, Carlotti A, Franck N, Dechelotte P, Souteyrand P, Courville P, Joly P, Delaunay M, Bagot M, Grange F, Fraitag S, Bosq J, Petrella T, Durlach A, De Mascarel A, Merlio JP, and Wechsler J
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Mycosis Fungoides immunology, Mycosis Fungoides mortality, Prognosis, Skin Neoplasms immunology, Skin Neoplasms mortality, Survival Rate, Cell Transformation, Neoplastic, Mycosis Fungoides pathology, Skin Neoplasms pathology
- Abstract
The course of mycosis fungoides (MF) is indolent except when transformation to a large T-cell lymphoma occurs. The diagnosis of transformed MF (T-MF) relies on the presence of more than 25% of large cells on biopsy of an MF lesion. We analyzed 45 patients with T-MF recorded by the French Study Group on Cutaneous Lymphomas to better determine clinicopathological features of MF transformation and to analyze their impact on prognosis. Median time from diagnosis of MF to transformation was 6.5 years. Extracutaneous progression was present in 20 patients. Mean survival from transformation to death was 22 months. In univariate analysis, only an extracutaneous progression was associated with a worse prognosis (5-year actuarial survival: 7.8% versus 32%). Neither sex, age, clinical and skin disease stage at transformation, transformation speed, nor percentage of large cells or CD30 expression (14 of 45) had a prognostic value. When performing multivariate analysis, age (at least 60 years), and extracutaneous spreading were found to be associated with a poor prognosis. There was no difference between survival curves of patients with T-MF and with pleomorphic large T-cell CD30- lymphomas. The main diagnostic pitfall was "histiocytic-rich" MF, requiring CD68 staining for the diagnosis of T-MF. Out of 45 patients, 6 presented an histologic transformation before clinical progression, suggesting that an early histopathological diagnosis may be performed by histological follow-up. The prognostic value of such early histopathological diagnosis must be confirmed by prospective studies.
- Published
- 2000
29. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas.
- Author
-
Grange F, Hedelin G, Joly P, Beylot-Barry M, D'Incan M, Delaunay M, Vaillant L, Avril MF, Bosq J, Wechsler J, Dalac S, Grosieux C, Franck N, Esteve E, Michel C, Bodemer C, Vergier B, Laroche L, and Bagot M
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, B-Lymphocytes pathology, Child, Female, Humans, L-Lactate Dehydrogenase blood, Lymphoma blood, Lymphoma physiopathology, Male, Middle Aged, Models, Statistical, Multivariate Analysis, Mycosis Fungoides pathology, Prognosis, Sex Factors, Sezary Syndrome pathology, Skin Neoplasms blood, Skin Neoplasms physiopathology, Survival Analysis, T-Lymphocytes pathology, Lymphoma pathology, Skin Neoplasms pathology
- Abstract
Prognostic studies of primary cutaneous lymphomas (PCL) other than mycosis fungoides (MF) and the Sézary syndrome (SS; non-MF/SS PCL) have been mainly performed on subgroups or on small numbers of patients by using univariate analyses. Our aim was to identify independent prognostic factors in a large series of patients with non-MF/SS PCL. We evaluated 158 patients who were registered in the French Study Group on Cutaneous Lymphomas database from January 1, 1986 to March 1, 1997. Variables analyzed for prognostic value were: age; sex; type of clinical lesions; maximum diameter, location, and number of skin lesions; cutaneous distribution (ie, local, regional, or generalized); prognostic group according to the European Organization for Research and Treatment of Cancer (EORTC) classification for PCL; B- or T-cell phenotype; serum lactate dehydrogenase (LDH) level; and B symptoms. Univariate and multivariate analyses were performed using a model of relative survival. Forty-nine patients (31%) died. The median relative survival time was 81 months. In univariate analysis, EORTC prognostic group, serum LDH level, B symptoms, and variables related to tumor extension (ie, distribution, maximum diameter, and number of skin lesions) were significantly associated with survival. When these variables were considered together in a multivariate analysis, EORTC prognostic group and distribution of skin lesions remained statistically significant, independent prognostic factors. This study confirms the good predictive value of the EORTC classification for PCL and shows that the distribution of skin lesions at initial evaluation is an important prognostic indicator.
- Published
- 1999
30. Looking for the agent: an investigation into consciousness of action and self-consciousness in schizophrenic patients.
- Author
-
Daprati E, Franck N, Georgieff N, Proust J, Pacherie E, Dalery J, and Jeannerod M
- Subjects
- Adult, Delusions etiology, Female, Hallucinations etiology, Humans, Male, Middle Aged, Schizophrenic Psychology, Consciousness physiology, Psychomotor Performance physiology, Schizophrenia, Self Concept
- Abstract
The abilities to attribute an action to its proper agent and to understand its meaning when it is produced by someone else are basic aspects of human social communication. Several psychiatric syndromes, such as schizophrenia, seem to lead to a dysfunction of the awareness of one's own action as well as of recognition of actions performed by others. Such syndromes offer a framework for studying the determinants of agency, the ability to correctly attribute actions to their veridical source. Thirty normal subjects and 30 schizophrenic patients with and without hallucinations and/or delusional experiences were required to execute simple finger and wrist movements, without direct visual control of their hand. The image of either their own hand or an alien hand executing the same or a different movement was presented on a TV-screen in real time. The task for the subjects was to discriminate whether the hand presented on the screen was their own or not. Hallucinating and deluded schizophrenic patients were more impaired in discriminating their own hand from the alien one than the non-hallucinating ones, and tended to misattribute the alien hand to themselves. Results are discussed according to a model of action control. A tentative description of the mechanisms leading to action consciousness is proposed.
- Published
- 1997
- Full Text
- View/download PDF
31. Necrotizing vasculitis and exacerbation of psoriasis after granulocyte colony-stimulating factor for small cell lung carcinoma.
- Author
-
Couderc LJ, Philippe B, Franck N, Balloul-Delclaux E, and Lessana-Leibowitch M
- Subjects
- Carcinoma, Small Cell therapy, Female, Humans, Lung Neoplasms therapy, Middle Aged, Granulocyte Colony-Stimulating Factor adverse effects, Psoriasis etiology, Vasculitis etiology
- Published
- 1995
- Full Text
- View/download PDF
32. [Cutaneous ulcerations in sarcoidosis].
- Author
-
de La Blanchardière A, Bachmeyer C, Toutous L, Franck N, Salmon D, Leibowitch M, and Sicard D
- Subjects
- Adult, Female, Humans, Mucous Membrane, Skin Ulcer diagnosis, Sarcoidosis complications, Skin Ulcer etiology
- Abstract
We report the case of a 23 year-old Caribbean woman with sarcoidosis who developed specific skin ulcerations. Ulcerative lesions in sarcoidosis are distinctly unusual, generally multiple, painless, with preponderant location on the lower limbs. The diagnosis is difficult. The pathogenesis is discussed. The most successful therapy is hydrochloroquine with corticosteroids.
- Published
- 1995
- Full Text
- View/download PDF
33. Ribozyme targeting of HIV-1 LTR.
- Author
-
Ventura M, Wang P, Franck N, and Saragosti S
- Subjects
- Base Sequence, Cell Line, Chloramphenicol O-Acetyltransferase genetics, Gene Expression, Gene Products, tat genetics, Gene Products, tat pharmacology, Genes, Reporter, Molecular Sequence Data, Plasmids, RNA, Catalytic antagonists & inhibitors, RNA, Catalytic chemistry, RNA, Messenger metabolism, Transfection, tat Gene Products, Human Immunodeficiency Virus, HIV Long Terminal Repeat genetics, HIV-1 genetics, RNA, Catalytic metabolism
- Abstract
The 5'-TAR region of HIV-1 mRNA is highly conserved amongst different HIV-1 isolates. We thus investigated the potential for in vivo targeting of the TAR RNA element by a hammerhead ribozyme. The use of the CAT reporter gene linked to the HIV1-LTR, in transient assays, reveals that a hammerhead ribozyme directed towards the first GUC of HIV-1 mRNA can efficiently inhibit CAT protein expression. We show that this inhibition is sequence-specific and probably due to a cleavage activity rather than an antisense effect. We show also that a hammerhead ribozyme that is inactive in vitro is capable of inhibiting CAT protein expression in a cellular environment. These results suggest that the targeting of the HIV-1 LTR by a hammerhead ribozyme constitutes a viable approach for anti-HIV therapy.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.